Search

Your search keyword '"Kalwak, K"' showing total 210 results
Start Over Author "Kalwak, K"
210 results on '"Kalwak, K"'

2. Results of Stem Cell Transplantation in Children with CML in Comparison with Treatment with Cytostatics alone or with Interferon alfa. Report of the Polish Children’s Leukemia/ Lymphoma Study Group

Author

Chybicka, A., Kalwak, K., Boguslawska-Jaworska, J., Balcerska, A., Balwierz, W., Cwiklinska, M., Hicke, A., Kaczmarek-Kanold, M., Kolecki, P., Kowalczyk, J., Krauze, A., Matysiak, M., Ploszynska, A., Rokicka-Milewska, R., Sonta-Jakimczyk, D., Sikorska-Fic, B., Wisniewska-Slusarz, H., Wysocki, M., Wachowiak, J., Berdel, W. E., editor, Büchner, Th., editor, Kienast, J., editor, Jürgens, H., editor, Ritter, J., editor, and Vormoor, J., editor

Published
2003
Full Text
View/download PDF

3. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome

Author

Albert, M.H., Slatter, M.A., Gennery, A.R., Gungor, T., Bakunina, K., Markovitch, B., Hazelaar, S., Sirait, T., Courteille, V., Aiuti, A., Aleinikova, O.V., Balashov, D., Bernardo, M.E., Bodova, I., Bruno, B., Cavazzana, M., Chiesa, R., Fischer, A., Hauck, F., Ifversen, M., Kalwak, K., Klein, C., Kulagin, A., Kupesiz, A., Kuskonmaz, B., Lindemans, C.A., Locatelli, F., Lum, S.H., Maschan, A., Meisel, R., Moshous, D., Porta, F., Sauer, M.G., Sedlacek, P., Schulz, A., Suarez, F., Vallee, T.C., Winiarski, J.H., Zecca, M., Neven, B., Veys, P., Lankester, A.C., EBMT, European Soc Immunodeficiencies ES, and Stem CELL Transplant Primary Immun

Subjects
Transplantation Conditioning, Immunology, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Cell Biology, Hematology, Biochemistry, Tissue Donors, Wiskott-Aldrich Syndrome, Treatment Outcome, surgical procedures, operative, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, immune system diseases, Child, Preschool, Humans, Busulfan, Retrospective Studies
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall survival, but some studies have identified older age and HSCT from alternative donors as risk factors predicting poorer outcome. We analyzed 197 patients undergoing transplant at European Society for Blood and Marrow Transplantation centers between 2006 and 2017 who received conditioning as recommended by the Inborn Errors Working Party (IEWP): either busulfan (n = 103) or treosulfan (n = 94) combined with fludarabine ± thiotepa. After a median follow-up post-HSCT of 44.9 months, 176 patients were alive, resulting in a 3-year overall survival of 88.7% and chronic graft-versus-host disease (GVHD)-free survival (events include death, graft failure, and severe chronic GVHD) of 81.7%. Overall survival and chronic GVHD-free survival were not significantly affected by conditioning regimen (busulfan- vs treosulfan-based), donor type (matched sibling donor/matched family donor vs matched unrelated donor/mismatched unrelated donor vs mismatched family donor), or period of HSCT (2006-2013 vs 2014-2017). Patients aged

Published
2022

5. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study

Author

Styczynski, J., Czyzewski, K., Wysocki, M., Gryniewicz-Kwiatkowska, O., Kolodziejczyk-Gietka, A., Salamonowicz, M., Hutnik, L., Zajac-Spychala, O., Zaucha-Prazmo, A., Chelmecka-Wiktorczyk, L., Siewiera, K., Fraczkiewicz, J., Malas, Z., Tomaszewska, R., Irga-Jaworska, N., Plonowski, M., Ociepa, T., Pierlejewski, F., Gamrot, Z., Urbanek-Dadela, A., Gozdzik, J., Stolpa, W., Dembowska-Baginska, B., Perek, D., Matysiak, M., Wachowiak, J., Kowalczyk, J., Balwierz, W., Kalwak, K., Chybicka, A., Badowska, W., Szczepanski, T., Drozynska, E., Krawczuk-Rybak, M., Urasinski, T., Mlynarski, W., Woszczyk, M., Karolczyk, G., Sobol-Milejska, G., and Gil, L.

Published
2016
Full Text
View/download PDF

18. Hematopoietic stem cell transplantation for CD40 ligand deficiency : Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study

Author

Ferrua, F., Galimberti, S., Courteille, V., Slatter, M.A., Booth, C., Moshous, D., Neven, B., Blanche, S., Cavazzana, M., Laberko, A., Shcherbina, A., Balashov, D., Soncini, E., Porta, F., Al-Mousa, H., Al-Saud, B., Al-Dhekri, H., Arnaout, R., Formankova, R., Bertrand, Y., Lange, A., Smart, J., Wolska-Kusnierz, B., Aquino, V.M., Dvorak, C.C., Fasth, A., Fouyssac, F., Heilmann, C., Hoenig, M., Schuetz, C., Kelecic, J., Bredius, R.G.M., Lankester, A.C., Lindemans, C.A., Suarez, F., Sullivan, K.E., Albert, M.H., Kalwak, K., Barlogis, V., Bhatia, M., Bordon, V., Czogala, W., Alonso, L., Dogu, F., Gozdzik, J., Ikinciogullari, A., Krivan, G., Ljungman, P., Meyts, I., Mustillo, P., Smith, A.R., Speckmann, C., Sundin, M., Keogh, S.J., Shaw, P.J., Boelens, J.J., Schulz, A.S., Sedlacek, P., Veys, P., Mahlaoui, N., Janda, A., Davies, E.G., Fischer, A., Cowan, M.J., Gennery, A.R., SCETIDE, PIDTC, EBMT, ESID IEWP, Ferrua, F, Galimberti, S, Courteille, V, Slatter, M, Booth, C, Moshous, D, Neven, B, Blanche, S, Laberko, A, Shcherbina, A, Balashov, D, Soncini, E, Porta, F, Al-Mousa, H, Al-Saud, B, Al-Dhekri, H, Arnaout, R, Formankova, R, Bertrand, Y, Lange, A, Smart, J, Wolska-Kusnierz, B, Aquino, V, Dvorak, C, Fasth, A, Fouyssac, F, Heilmann, C, Hoenig, M, Schuetz, C, Kelečić, J, Bredius, R, Lankester, A, Lindemans, C, Suarez, F, Sullivan, K, Albert, M, Kałwak, K, Barlogis, V, Bhatia, M, Bordon, V, Czogala, W, Alonso, L, Dogu, F, Gozdzik, J, Ikinciogullari, A, Kriván, G, Ljungman, P, Meyts, I, Mustillo, P, Smith, A, Speckmann, C, Sundin, M, Keogh, S, Shaw, P, Boelens, J, Schulz, A, Sedlacek, P, Veys, P, Mahlaoui, N, Janda, A, Davies, E, Fischer, A, Cowan, M, and Gennery, A

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, Immunology, Hematopoietic stem cell transplantation, X-Linked Combined Immunodeficiency Diseases, primary immunodeficiency, Donor lymphocyte infusion, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, X-linked hyper-IgM syndrome, Humans, Medicine, Immunology and Allergy, Risk factor, Child, Prospective cohort study, business.industry, Infant, Newborn, Infant, medicine.disease, Treatment Outcome, 030104 developmental biology, medicine.anatomical_structure, Graft-versus-host disease, surgical procedures, operative, Supportive psychotherapy, Child, Preschool, hematopoietic stem cell transplantation, Primary immunodeficiency, Bone marrow, CD40 ligand, business, 030215 immunology
Abstract

BACKGROUND: CD40 ligand (CD40L) deficiency, an X-linked primary immunodeficiency, causes recurrent sinopulmonary, Pneumocystis and Cryptosporidium species infections. Long-term survival with supportive therapy is poor. Currently, the only curative treatment is hematopoietic stem cell transplantation (HSCT). OBJECTIVE: We performed an international collaborative study to improve patients' management, aiming to individualize risk factors and determine optimal HSCT characteristics. METHODS: We retrospectively collected data on 130 patients who underwent HSCT for CD40L deficiency between 1993-2015. We analyzed outcome and variables' relevance with respect to survival and cure. RESULTS: Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3% 5 years after HSCT. Results were better in transplantations performed in 2000 or later and in children less than 10 years old at the time of HSCT. Pre-existing organ damage negatively influenced outcome. Sclerosing cholangitis was the most important risk factor. After 2000, superior OS was achieved with matched donors. Use of myeloablative regimens and HSCT at 2 years or less from diagnosis associated with higher OS and DFS. EFS was best with matched sibling donors, myeloablative conditioning (MAC), and bone marrow-derived stem cells. Most rejections occurred after reduced-intensity or nonmyeloablative conditioning, which associated with poor donor cell engraftment. Mortality occurred mainly early after HSCT, predominantly from infections. Among survivors who ceased immunoglobulin replacement, T-lymphocyte chimerism was 50% or greater donor in 85.2%. CONCLUSION: HSCT is curative in patients with CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with better OS, EFS, and DFS. Prospective studies are required to compare the risks of HSCT with those of lifelong supportive therapy. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol:143 issue:6 pages:2238-2253 ispartof: location:United States status: published

Published
2019

29. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents

Author

Millot F., Dupraz C., Guilhot J., Suttorp M., Brizard F., Leblanc T., Gunes A. M., Sedlacek P., De Bont E., Li C. K., Kalwak K., Lausen B., Culic S., Dworzak M., Kaiserova E., De Moerloose B., Roula F., Biondi A., Baruchel A., Guilhot F., Millot, F, Dupraz, C, Guilhot, J, Suttorp, M, Brizard, F, Leblanc, T, Gunes, A, Sedlacek, P, De Bont, E, Li, C, Kalwak, K, Lausen, B, Culic, S, Dworzak, M, Kaiserova, E, De Moerloose, B, Roula, F, Biondi, A, Baruchel, A, and Guilhot, F

Subjects
Registrie, Internationality, Chromosomes, Human, Pair 22, Kaplan-Meier Estimate, Real-Time Polymerase Chain Reaction, Chromosome Aberration, Disease-Free Survival, Drug Administration Schedule, Statistics, Nonparametric, Follow-Up Studie, chronic myeloid leukemia, Retrospective Studie, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, Humans, Genetic Predisposition to Disease, Philadelphia-positive, Registries, Retrospective Studies, Chromosome Aberrations, child, Antineoplastic Combined Chemotherapy Protocol, Dose-Response Relationship, Drug, cytogenetic, Survival Analysis, Treatment Outcome, imatinib, Survival Analysi, Chromosomes, Human, Pair 9, Human, Follow-Up Studies
Abstract

BACKGROUND: In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. METHODS: The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. RESULTS: Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98%), and 75% (95% CI, 13%-96%), respectively. No statistical difference was observed between the patients with classic cytogenetic findings and those with additional chromosomal abnormalities in terms of PFS and OS. CONCLUSIONS: In contrast to adults with CML, additional chromosomal abnormalities observed at diagnosis do not seem to have a significant prognostic impact. Cancer 2017;123:3609-16. © 2017 American Cancer Society.

Published
2017

35. G-CSF Vs Haematopoietic Stem Cell Transplantation in Severe Congenital Neutropenia with ELANE Mutation: Role of G-CSF Dose. a Retrospective Controlled Study on Behalf of Saawp (Severe Aplastic Anemia Working Party) of the EBMT, of the Stem Cell Transplant for Immunodeficiency Group in Europe (SCETIDE), of the Severe Chronic Neutropenia French Registry (SCNFR) and Italian Neutropenia Registry (INR)

Author

Fioredda, F, Pierri, F, Zanardi, S, Gaspar, B, Ancliff, P, Bierings, M, Ozturk, G, Smith, O, Veys, P, Ljungman, P, De Latour, Rp, Or, R, Wynn, R, Kalwak, K, Russo, G, Tucci, F, Knoll, Cm, Martire, B, Favre, C, Chantelot, Cb, Beaupain, B, Donadieu, J, and Dufour, C

Published
2017

38. Haematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT Inborn Errors Working Party (IEWP) study

Author

Ferrua, F., Courteille, V., Janda, A., Slatter, M., Albert, M.H., Al-Mousa, H., Al-Saud, B., Balashov, D., Bertrand, Y., Booth, C., Bordon, V., Czogala, W., Dogu, F., Fasth, A., Formankova, R., Gozdzik, J., Heilmann, C., Honig, M., Ikinciogullari, A., Kalwak, K., Keogh, S.J., Krivan, G., Lange, A., Lankester, A.C., Ljungman, P., Meyts, I., Neven, B., Soncini, E., Suarez, F., Mahlaoui, N., Fischer, A., Davies, E.G., Gennery, A.R., and EBMT IEWP

Published
2015

39. Stem cell transplantation in severe congenital neutropenia: An analysis from the European Society for Blood and Marrow Transplantation

Author

Fioredda, F., Iacobelli, S., Biezen, A. van, Gaspar, B., Ancliff, P., Donadieu, J., Aljurf, M., Peters, C., Calvillo, M., Matthes-Martin, S., Morreale, G., van't Veer-Tazelaar, N., Wreede, L. de, Seraihy, A. al, Yesilipek, A., Fischer, A., Bierings, M., Ozturk, G., Smith, O., Veys, P., Ljungman, P., Latour, R.P. de, Codina, J.S.D., Or, R., Ganser, A., Afanasyev, B., Wynn, R., Kalwak, K., Marsh, J., Dufour, C., Pediat Dis Working Parties Europea, Fioredda, Francesca, Iacobelli, Simona, Van Biezen, Anja, Gaspar, Bobby, and Risitano, ANTONIO MARIA

Subjects
Male, Graft Rejection, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, Biochemistry, Allograft, Retrospective Studie, Cumulative incidence, Non-U.S. Gov't, Child, Societies, Medical, Incidence (epidemiology), Research Support, Non-U.S. Gov't, Histocompatibility Testing, Incidence, Medicine (all), Hematopoietic Stem Cell Transplantation, Hematology, Allografts, Clinical Trial, Multicenter Study, Europe, surgical procedures, operative, Child, Preschool, Acute Disease, Cyclosporine, Female, Unrelated Donors, Kostmann syndrome, Human, Adult, medicine.medical_specialty, Neutropenia, Adolescent, Immunology, Research Support, Settore MED/01 - Statistica Medica, Middle East, Internal medicine, Medical, medicine, Journal Article, Humans, Aplastic anemia, Congenital Neutropenia, Preschool, Retrospective Studies, business.industry, Unrelated Donor, Cell Biology, medicine.disease, Surgery, Transplantation, Methotrexate, business, Societies
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment of severe congenital neutropenia (SCN), but data on outcome are scarce. We report on the outcome of 136 SCN patients who underwent HSCT between 1990 and 2012 in European and Middle East centers. The 3-year overall survival (OS) was 82%, and transplant-related mortality (TRM) was 17%. In multivariate analysis, transplants performed under the age of 10 years, in recent years, and from HLA-matched related or unrelated donors were associated with a significantly better OS. Frequency of graft failure was 10%. Cumulative incidence (day +90) of acute graft-versus-host disease (GVHD) grade 2-4 was 21%. In multivariate analysis, HLA-matched related donor and prophylaxis with cyclosporine A and methotrexate were associated with lower occurrence of acute GVHD. Cumulative incidence (1 year) of chronic GVHD was 20%. No secondary malignancies occurred after a median follow-up of 4.6 years. These data show that the outcome of HSCT for SCN from HLA-matched donors, performed in recent years, in patients younger than 10 years is acceptable. Nevertheless, given the TRM, a careful selection of HSCT candidates should be undertaken.

Published
2015

40. Survey of presentation, management and outcome of children with X-linked lynphoproliferative disorder

Author

Booth C., Gilmour K., Gennery A., Arkwright P., Plebani A., Soresina A., Finocchi A., Broccoletti T. Notheis G., Albert M., Meyls I., Kalwak K., Pasic S., Gaspar B., PIGNATA, CLAUDIO, Booth, C., Gilmour, K., Gennery, A., Arkwright, P., Plebani, A., Soresina, A., Finocchi, A., Pignata, Claudio, Broccoletti, T. Notheis G., Albert, M., Meyls, I., Kalwak, K., Pasic, S., and Gaspar, B.

Published
2009

41. HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE CONGENITAL NEUTROPENIA: DATA FROM THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION

Author

Fioredda, F., Wreede, L. C., Biezen, A., T Veer-Tazelaar, N., Michaela Calvillo, Gaspar, B., Aljurf, M., Peters, C., Yesilipek, A., Fisher, A., Bierings, M., Donadieu, J., Ozturk, G., Ljungman, P., Or, R., Ganser, A., Veys, P., Matthes-Martin, S., Kalwak, K., Wynn, R., Afanasyev, B., Toledo Codina, J. S., Marsh, J., and Dufour, C.

Published
2014

42. Lymphoproliferative Disorders After Hematopoietic Stem Cell Transplantation in Children and Adults: a Study From the Infectious Diseases Working Group of the European Group for Blood and Marrow Transplantation

Author

Styczynski, J, Gil, L, Tridello, G, Ljungman, P, Donnelly, J, Null, V, Omar, H, Martino, R, Halkes, C, Faraci, M, Theunissen, K, Kalwak, K, Hubacek, P, Sica, S, Nozzoli, C, Fagioli, F, Matthes, S, Diaz, M, Migliavacca, M, Balduzzi, A, Tomaszewska, A, Null, C, Null, B, Hoek, J, Iacobelli, S, Einsele, H, and Cesaro S, E

Subjects
Settore MED/01 - Statistica Medica
Published
2013

44. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?

Author

Fernandes, Jf, Rocha, V, Labopin, M, Neven, B, Moshous, D, Gennery, Ar, Friedrich, W, Porta, F, Diaz de Heredia, C, Wall, D, Bertrand, Y, Veys, P, Slatter, M, Schulz, A, Chan, Kw, Grimley, M, Ayas, M, Gungor, T, Ebell, W, Bonfim, C, Kalwak, K, Taupin, P, Blanche, S, Gaspar, Hb, Landais, P, Fischer, A, Gluckman, E, Cavazzana Calvo, M, Eurocord, Inborn Errors Working Party of European Group for Blood, Marrow Transplantation: Ahmed, A, Auiti, A, Biffi, A, Cant, A, Fasth, A, Gennery, A, Hassan, A, Lankester, A, O'Mera, A, Plabani, A, Rovelli, A, Salmon, A, Scarselli, A, Thrasher, A, Van Royen, A, Villa, A, Wawer, A, Wahadneh, A, Worth, A, Belohradsky, B, Wolska, B, Gaspar, B, Bonfirm, C, Booth, C, Klein, C, Messina, C, Peters, C, Steward, C, Lindemans, C, Schuetz, C, de Heredia Rubio CD, Bensoussan, D, Gleadow, D, Lilic, D, Gambineri, Eleonora, Smith, E, Aerts, F, Caracseghi, F, Roberts, G, Davies, G, Al Mousa, H, Jossanc, H, Ozsahim, H, Hirsch, I, Meyts, I, Tezcan, I, Mueller, I, Andresc, I, Boelens, J, Fernandes, J, Folloni, J, Keuhl, J, Reichenbach, J, Stary, J, Wachowiak, J, Xu Bayford, J, Cunha, Jm, Ehlert, J, Rao, K, Sykora, K, Andais, L, Brown, L, Dal Cortivo, L, Griffith, L, Notarangelo, L, Abinun, M, Albert, M, Bierings, M, Bouchet, M, Cavazzana, M, Hirschfield, M, Cowan, M, Hoenig, M, Loubser, M, Roncarolo, M, Sauer, M, Schneider, M, Verstegen, M, Schroeder, M, Essink, M, Yesilipek, M, Entz Werle, N, Mahlaoui, N, Schlautmann, N, Taylor, N, Vanroyen, N, Walffraat, N, Sanal, O, Amrolia, P, Bordigoni, P, De Coppi, P, Frange, P, Orchard, P, Sedlacek, P, Shaw, P, Stephensky, P, Bacchetta, R, Bredius, R, Formankova, R, Gale, R, Seger, R, Wynn, R, Corbacioglu, S, Ehl, S, Hacein Bey, S, Hambleton, S, Mohsen, S, Mueller, S, Pai, Sy, Espanol, T, Flood, T, Guengoer, T, Bordon, V, Ormoor, V, Pashano, V, Courteille, V, Czogala, W, Qasim, W, Camci, Y, and Nademi, Z.

Subjects
Male, medicine.medical_specialty, Transplantation Conditioning, medicine.medical_treatment, Immunology, Graft vs Host Disease, Kaplan-Meier Estimate, Cord Blood Stem Cell Transplantation, Hematopoietic stem cell transplantation, Biochemistry, Gastroenterology, SCID HSCT, Internal medicine, medicine, Humans, Proportional Hazards Models, Retrospective Studies, Preparative Regimen, Severe combined immunodeficiency, business.industry, Umbilical Cord Blood Transplantation, Incidence, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Infant, Cell Biology, Hematology, medicine.disease, Surgery, Transplantation, Treatment Outcome, Child, Preschool, Histocompatibility, Cord blood, Female, Severe Combined Immunodeficiency, business
Abstract

Pediatric patients with SCID constitute medical emergencies. In the absence of an HLA-identical hematopoietic stem cell (HSC) donor, mismatched related-donor transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable treatment options. To help transplantation centers choose the best treatment option, we retrospectively compared outcomes after 175 MMRDTs and 74 UCBTs in patients with SCID or Omenn syndrome. Median follow-up time was 83 months and 58 months for UCBT and MMRDT, respectively. Most UCB recipients received a myeloablative conditioning regimen; most MMRDT recipients did not. UCB recipients presented a higher frequency of complete donor chimerism (P = .04) and faster total lymphocyte count recovery (P = .04) without any statistically significance with the preparative regimen they received. The MMRDT and UCBT groups did not differ in terms of T-cell engraftment, CD4+ and CD3+ cell recoveries, while Ig replacement therapy was discontinued sooner after UCBT (adjusted P = .02). There was a trend toward a greater incidence of grades II-IV acute GVHD (P = .06) and more chronic GVHD (P = .03) after UCBT. The estimated 5-year overall survival rates were 62% ± 4% after MMRDT and 57% ± 6% after UCBT. For children with SCID and no HLA-identical sibling donor, both UCBT and MMRDT represent available HSC sources for transplantation with quite similar outcomes.

Published
2012

45. Use of rituximab for post-SCT EBV-PTLD: the final results of a retrospective EBMT study

Author

Styczynski, J., Gil, L., Donnelly, J. P., Ljungman, P., Martino, R., Halkes, S., Theunissen, K., Maertens, J., Kalwak, K., Hubacek, P., Sica, S., van der Velden, W., Omar, H., Nozzoli, C., Fagioli, F., Matthes, S., Diaz, M. A., Migliavacca, M., Balduzzi, A., Faraci, M., de la Camara, A. Tomaszewska R., van Biezen, A., Tridello, G., Einsele, H., and Cesaro, Simone

Subjects
rituximab, PTLD, rituximab, PTLD, stem cell transplantation, stem cell transplantation
Published
2012

46. Long-term outcome following hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and the European Group for Blood and Marrow Transplantation

Author

Ozsahin, H, CAVAZZANA CALVO, M, Notarangelo, Luigi Daniele, Schulz, A, Thrasher, Aj, Mazzolari, Evelina, Slatter, Ma, LE DEIST, F, Blanche, S, Veys, P, Fasth, A, Bredius, R, Sedlacek, P, Wulfraat, N, Ortega, J, Heilmann, C, O'Meara, A, Wachowiak, J, Kalwak, K, MATTHES MARTIN, S, Gungor, T, Ikinciogullari, A, Landais, P, Cant, Aj, Friederich, W, and Fisher, A.

Published
2007

48. Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder in Children Treated with Rituximab: The Impact of Viral Load and Non-Lymphoid Tissue Involvement

Author

Styczynski, J., primary, Gil, L., additional, Ljungman, P., additional, Donnelly, J.P., additional, Martino, R., additional, Theunissen, K., additional, Maertens, J., additional, Kalwak, K., additional, Hubacek, P., additional, Sica, S., additional, van der Velden, W., additional, Omar, H., additional, Nozzoli, C., additional, Fagioli, F., additional, Matthes, S., additional, Diaz, M.A., additional, Migliavacca, M., additional, Balduzzi, A., additional, Faraci, M., additional, Tomaszewska, A., additional, de la Camara, R., additional, Hoek, J., additional, Einsele, H., additional, and Cesaro, S., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results